Clinical efficacy of dendritic cell vaccine combined with radiofrequency ablation in colorectal cancer patients with liver metastasis
Article
Figures
Metrics
Preview PDF
Reference
Related
Cited by
Materials
Abstract:
Objective:To explore the clinical efficacy of dendritic cell vaccine combined with radiofrequency ablation (RFA) for treatment of colorectal liver metastasis (CRLM) patients. Methods: Forty-six patients with comfirmed CRLM underwent RFA in 81st Hospital of PLA from Aug. 2012 to Aug. 2014 were retrospectively analyzed, the patients were randomly divided into 2 groups: DC treatment combined with RFA group (n=26) and treatment group RFA control (n=20). After treatment, the two groups were compared for the recent curative effect, the long-term curative effect, immune function, safety and improvement in quality of life.Results:(1) The significant differences was found in the overall response rate between DC-RFA group and RFA group (92.31% vs 70.00%, P<0.05); the six month survival rate of DC-RFA group and RFA group was 96.15% and 90.00% respectively. The 1- and 2- year survival rate of DC-RFA groups was slightly less better than that of RFA group(P>0.05); (2) in DC-RFA group, percentage of CD3+ and CD4+ the ratio of CD4+/CD8+ in peripheral blood increased significantly (P<0.05), but CD8+ reduced (P>0.05) after the treatment ; In the RFA group, percentage of CD3+and CD4+, the ratio of CD4+/CD8+ increased remarkably after treatment(P<005), while CD8+ slightly increased(P>005). (3) In DC-RFA group, there were 2 cases of fever, 1 case of allergic reaction, and the patients recovered after treatment. (4) The life quality of the patients was improved in the DC-RFA group, especially in the aspects of mental state and pain control. Conclusion:In the treatment of patients with CRLM, DC vaccine combined with RFA can improve the therapeutic effect of RFA treatment, prolong the survival time, improve the immune function, and can effectively improve the quality of life and possess good treatment safety.